• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Lunit and Daiichi Sankyo Partner to Accelerate Cancer Biomarker Discovery with AI

by Jasmine Pennic 12/15/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Lunit has announced a collaboration with pharmaceutical giant Daiichi Sankyo to integrate its AI-powered Lunit SCOPE digital pathology products into two of Daiichi Sankyo’s oncology pipeline programs.

– The partnership will utilize Lunit’s SCOPE uIHC and SCOPE IO solutions to analyze pathology slides for quantitative data and immune phenotyping, aiming to discover novel biomarkers and improve patient stratification for clinical trials. This move underscores the growing role of AI in accelerating translational research and enabling more precise, data-driven drug development.

From Slides to Insights: Lunit and Daiichi Sankyo Bet on AI to Refine Oncology R&D

For decades, pathology has been a discipline of visual pattern recognition—highly skilled experts looking at slides under a microscope. But in the era of precision medicine, the human eye alone cannot quantify the complex data hidden within the tumor microenvironment. Today, Lunit (KRX:328130) announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to bridge this gap, deploying AI to turn tissue samples into actionable data for drug development.

The partnership focuses on integrating Lunit’s SCOPE digital pathology suite into two of Daiichi Sankyo’s oncology pipeline programs. This is not merely a vendor agreement; it represents a strategic shift toward using computational pathology to “de-risk” clinical trials by better understanding which patients are most likely to respond to experimental therapies.

The Tech Stack: SCOPE uIHC and IO

At the heart of the deal are two specific AI tools:

  • SCOPE uIHC: Designed for quantitative immunohistochemistry (IHC) analysis. This tool automates the quantification of protein expression, reducing the variability inherent in manual scoring.
  • SCOPE IO: Focused on immune phenotyping and spatial analysis. This tool maps the tumor microenvironment, identifying the spatial relationship between immune cells and cancer cells—a critical factor in predicting responses to immunotherapies.

“Lunit SCOPE was built to unlock hidden insights from pathology slides—quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit.

Optimizing Translational Research

The collaboration will span exploratory research projects across multiple cancer types. By applying these AI models, Daiichi Sankyo aims to identify novel biomarkers that might otherwise go unnoticed.

In the high-stakes world of oncology R&D, where the failure rate for new drugs is notoriously high, this kind of data enrichment is invaluable. It allows researchers to potentially “enrich” clinical trials—selecting patients based on a precise biomarker profile rather than broad clinical criteria. This stratification can lead to smaller, faster, and more successful trials.

“By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification,” Suh added. “Ultimately, this means… where each patient has a greater chance of receiving the therapy that works best for them.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Biomarker-Guided Drug Development, Biomarkers, Drug Discovery

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |